EN DE
Watch Erasca Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Erasca Inc (ERAS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Erasca Inc stock $9.08, price $15.48, that is 41.3% below the price, quality 41 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

EI Erasca Inc logo Thin data Nov 10, 2026

Erasca Inc

ERAS · US
Very expensive, weak quality

Our calculation puts a fair price 41% below what the stock costs today.

Quality 41/100
Mixed vs. peers (3/7)
Fair value $9.08 · Strongly overvalued
Negative free cash flow
Narrow moat 10/100 · thin data
Downbeat coverage
Thin data
Estimate
Watch Erasca Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$24.34 $1.06 Fair Value $9.08 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $1.06 – $24.34 · fair‑value band $6.81 – $11.35 · the $15.48 price screens above the $9.08 fair value. As of Nov 10, 2026.

Follow Erasca in your weekly email

Every Wednesday you see whether Erasca is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

Show moreShow less

The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.

It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds.

The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Stock analysis

Erasca Inc (ERAS) currently trades at $15.48, while our estimate is $9.08, 41% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $6.81 (bear) to $11.35 (bull), the price of $15.48 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Erasca Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$125M in FY2025.

Key figures

Market cap $4.8B Mid · EPS (TTM) $−0.9500 · Return on equity −78.3% · Return on assets (EBIT) −35.5% (5-year average) · Free cash flow −$95.6M · Net cash $26.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 576% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −41%, ERAS screens richer than that median.

Fair Value

Bear $6.81 Fair Value $9.08 Bull $11.35
Price $15.48 · Downside -41.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 54
Are margins and returns getting better?
Cashflow 18
Do the profits arrive as real cash?
Financial strength 91
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 44
How calm the share price moves, does not count
Price momentum 76
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 83
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleEbun GarnerChief Legal Officer2× since Jan 7, 2026: 200,000 shares, avg. $9.91$2.0MApr 1, 202610b5-1 plan
  • SaleShannon MorrisChief Medical Officer20,000 shares at $15.04$300,800Mar 4, 202610b5-1 plan

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ERAS screens overvalued: fair value 41% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (74 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.

Compare Erasca Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 41 · Above median
Fair Value upside −41.3% · Below median
Profitability
Return on assets −31.4% · Below median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 14.82× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs ERAS
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs ERAS
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs ERAS
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs ERAS
argenx SE ARGX $971.55 $908.40 −7% vs ERAS
CSL Limited CSL A$201.68 A$181.40 −10% vs ERAS
Moderna, Inc MRNA $250.83 $158.70 −37% vs ERAS
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs ERAS
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs ERAS
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs ERAS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Erasca Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Erasca Inc Fair Value". https://www.fairvalue-calculator.com/stock/ERAS

Frequently asked questions

Is Erasca Inc (ERAS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $9.08 versus a price of $15.48, about 41% lower (overvalued).
What is the fair value of ERAS?
Our estimate for Erasca Inc is $9.08 (as of Nov 10, 2026), built from audited fundamentals. The current price: $15.48.
What is the quality score of ERAS?
Erasca Inc has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Erasca Inc (ERAS)?
Our calculated price target is the estimate of $9.08 (as of Nov 10, 2026). Cautious scenario $6.81, optimistic scenario $11.35. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Erasca Inc stock forecast for 2026?
Our estimate puts fair value at $9.08, about 41% lower versus a price of $15.48 (overvalued). Cautious scenario $6.81, optimistic scenario $11.35. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Erasca Inc (ERAS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Erasca Inc it is $9.08 per share (as of Nov 10, 2026), against a price of $15.48.
Is Erasca Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ERAS trades above its calculated fair value: price $15.48, fair value $9.08, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ERAS?
No. The price is what the market pays today ($15.48); the fair value is what the company's own numbers justify ($9.08). For Erasca Inc the two are $6.40 per share apart. That gap is exactly why we show both numbers side by side.
How much is Erasca Inc worth?
The market values Erasca Inc at about $4.8B (market capitalisation, as of Nov 10, 2026). Per share that is $15.48; our models calculate a fair value of $9.08 per share.
What do the bullish and bearish scenarios say about ERAS?
Our models span a range for Erasca Inc: cautious scenario $6.81, base $9.08, optimistic $11.35 per share (as of Nov 10, 2026, price $15.48). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Erasca Inc (ERAS)?
Balance-sheet figures for Erasca Inc (as of Nov 10, 2026): return on equity −78.3%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is ERAS from its 52-week high?
Erasca Inc trades at $15.48, about 31% below its 52-week high of $22.47 and 576% above the low of $2.29 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $9.08 is for.
Which stocks are comparable to Erasca Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Erasca Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $15.48, calculated fair value $9.08 (−41%), Quality Score 41/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Erasca Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Erasca Inc (ERAS)?
The closing price on Nov 10, 2026 was $15.48. Our estimate is $9.08, about 41% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Erasca Inc right now?
The price sits above even our optimistic bull case ($11.35). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Erasca Inc

How large is the market capitalisation of Erasca Inc (ERAS)?
The market capitalisation of Erasca Inc is $4.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Erasca Inc (ERAS)?
Earnings per share at Erasca Inc are $−0.9500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Erasca Inc (ERAS)?
The return on equity (ROE) of Erasca Inc is −78.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Erasca Inc (ERAS)?
On an EBIT basis the return on assets of Erasca Inc is −35.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Erasca Inc (ERAS) generate?
The free cash flow of Erasca Inc is −$95.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Erasca Inc (ERAS) hold?
Erasca Inc holds more cash than debt, $26.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Erasca Inc in the live analysis

One click puts Erasca Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.